Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Receivables - Other: 2019-2020

Historic Receivables - Other for Revolution Medicines (RVMD) over the last 1 years, with Dec 2020 value amounting to $6.4 million.

  • Revolution Medicines' Receivables - Other fell 26.83% to $6.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was $6.4 million, marking a year-over-year decrease of 26.83%. This contributed to the annual value of $6.4 million for FY2020, which is 26.83% down from last year.
  • According to the latest figures from Q4 2020, Revolution Medicines' Receivables - Other is $6.4 million, which was down 31.25% from $9.3 million recorded in Q3 2020.
  • Over the past 5 years, Revolution Medicines' Receivables - Other peaked at $9.3 million during Q3 2020, and registered a low of $6.4 million during Q4 2020.
  • In the last 2 years, Revolution Medicines' Receivables - Other had a median value of $8.4 million in 2020 and averaged $8.0 million.
  • Data for Revolution Medicines' Receivables - Other shows a maximum YoY dropped of 26.83% (in 2020) over the last 5 years.
  • Quarterly analysis of 2 years shows Revolution Medicines' Receivables - Other stood at $8.7 million in 2019, then dropped by 26.83% to $6.4 million in 2020.
  • Its Receivables - Other stands at $6.4 million for Q4 2020, versus $9.3 million for Q3 2020 and $7.3 million for Q2 2020.